Showing 2261-2270 of 4063 results for "".
- Two-Year Results for Aflibercept 8 mg from PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in DMEhttps://modernod.com/news/two-year-results-for-aflibercept-8-mg-from-photon-trial-demonstrate-durable-vision-gains-at-extended-dosing-intervals-in-dme/2481696/Regeneron released on Tuesday topline, 2-year (96 weeks) data for aflibercept 8 mg from the PHOTON trial in patients with diabetic macular edema (DME). During the trial, aflibercept 8 mg patients were initially randomized to either 12- or 16-week dosing intervals (after three initial monthly
- Aldeyra Therapeutics Achieves Statistical Significance for All Endpoints in Phase 3 Trial of Reproxalap in Allergic Conjunctivitishttps://modernod.com/news/aldeyra-therapeutics-achieves-statistical-significance-for-primary-and-secondary-endpoints-in-phase-3-trial-of-reproxalap-in-allergic-conjunctivitis-1/2481676/Aldeyra Therapeutics announced positive topline results from the phase 3 INVIGORATE-2 clinical trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational new drug, in patients with allergic conjunctivitis. The clinical trial successfully achieved statistical significance for t
- Aviceda Announces Dosing of First Patient With AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of GAhttps://modernod.com/news/aviceda-announces-dosing-of-first-patient-with-avd-104-a-novel-glyco-mimetic-nanoparticle-for-the-treatment-of-ga/2481647/Aviceda Therapeutics announced the dosing of its first patient with AVD-104 in its phase 2 SIGLEC trial by Ashkan Abbey, MD, of Texas Retina Associates in Dallas. This lead intravitreal asset is a novel glycan-coated nanoparticle, supported by a uniquely strong preclinical in
- Sight Sciences: Two Year Study Results Show Sustained Reductions in IOP and Glaucoma Medication Use with Omni Treatmenthttps://modernod.com/news/sight-sciences-two-year-study-results-show-sustained-reductions-in-iop-and-glaucoma-medication-use-in-mild-moderate-poag-patients-treated-with-omni/2481630/Sight Sciences announced the publication of 2-year results of the ROMEO (Retrospective, Observational, Multicenter, Evaluation of OMNI) study in Clinical Ophthalmology. The longest multicenter study of the Omni Surgical System technology to date in both standalone and comb
- AI-based Systems Can Help Identify Rapidly Advancing Age-Related Macular Degenerationhttps://modernod.com/news/ai-based-systems-can-help-identify-rapidly-advancing-age-related-macular-degeneration/2481490/Researchers supported by the National Eye Institute (NEI) are developing artificial intelligence/machine learning (AI/ML)-based systems that not only screen for AMD but also predict which patients will likely progress to late within 2 years,
- Cognition Therapeutics Announces Development Plans for Oral CT1812 in GA Secondary to Dry AMDhttps://modernod.com/news/cognition-therapeutics-announces-development-plans-for-oral-ct1812-in-ga-secondary-to-dry-amd/2481472/Cognition Therapeutics announced that its investigational new drug (IND) application for CT1812 for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) has been cleared by the FDA. Cognition plans to initiate the phase 2 MAGNIFY trial of its oral drug candidate&nb
- Iridex Introduces New Research and Showcases Five Events at the AGS Meetinghttps://modernod.com/news/iridex-introduces-new-research-and-showcases-five-events-at-the-ags-meeting/2481441/Iridex announced Part 2 of the evidence-based guidelines series for MicroPulse Transscleral Laser Therapy (TLT) has been published in Clinical Ophthalmology by the international consensus panel of ten glaucoma experts[1].The publication will be available at booth #5 at the 2023 meet
- Post-Hoc Analysis Shows Up to a 59% Reduction in Rate of Vision Loss in Iveric Bio's GA Treatmenthttps://modernod.com/news/iveric-bio-announces-up-to-a-59-reduction-in-rate-of-vision-loss-in-geographic-atrophy-treatment-trials/2481439/Iveric bio announced an exploratory time-to-event analysis from the avacincaptad pegol (ACP) GATHER clinical trial program evaluating reduction in vision loss with ACP 2 mg versus sham treatment. The GATHER1 and GATHER2 clinical trials were designed to evaluate the rate of geographic at
- Glaucoma Research Foundation to Recognize Santen Pharmaceutical at Annual Gala in San Franciscohttps://modernod.com/news/glaucoma-research-foundation-to-recognize-santen-pharmaceutical-at-annual-gala-in-san-francisco/2481369/Santen Pharmaceutical will receive the Glaucoma Research Foundation's Catalyst Award at the Glaucoma 360 Annual Gala on February 2, 2023, in San Francisco, the foundation's President and CEO Thomas M. Brunner announced. Santen is being recognized for th
- Oculis Completes Patient Recruitment for Stage 1 of Phase 3 DIAMOND Study Evaluating the Efficacy and Safety of OCS-01 in DMEhttps://modernod.com/news/oculis-completes-patient-recruitment-for-stage-1-of-phase-3-diamond-study-evaluating-the-efficacy-and-safety-of-ocs-01-in-dme/2481323/Oculis announced the completion of enrollment for stage 1 of its phase 3 DIAMOND (DIAbetic Macular edema patients ON a Drop) study evaluating the efficacy and safety of OCS-01 in patients with diabetic macular edema (DME). At the end of 2021, Oculis launched its 2-stage,